Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties

INTRODUCTION: Histone deacetylase inhibitors (HDIs) are a group of compounds that exhibit anticancer activity, but their significance and usefulness in breast cancer (BC) treatment are still controversial. The ability of cancer cells to invade and migrate is augmented by the acquisition of a mesench...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Wawruszak, Anna, Gumbarewicz, Ewelina, Okon, Estera, Jeleniewicz, Witold, Czapinski, Jakub, Halasa, Marta, Okla, Karolina, Smok-Kalwat, Jolanta, Bocian, Artur, Rivero-Muller, Adolfo, Stepulak, Andrzej
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6750858/
https://ncbi.nlm.nih.gov/pubmed/31571991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S210029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars